Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,430.59
(
-0.94%
)
US TECH 100
28,440.20
(
-1.22%
)
Dow Jones
49,572.47
(
-0.98%
)
Brent Oil
106.61
(
2.33%
)
Bitcoin
79,236.42
(
-2.25%
)
News Focus
News Focus
Post# of 257574
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122986
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 88806

Sunday, 01/10/2010 8:20:35 PM

Sunday, January 10, 2010 8:20:35 PM

Post# of 257574
(ABT/ANDS/BMY/IDIX/VRUS) Addendum re today’s VRTX PR:

Based on VRTX’s newfound interest in keeping the VX-222 DDI and monotherapy data under wraps, one could infer that the VX-222 data are less than stellar. If true, this is bullish for such companies as ABT, ANDS, BMY, IDIX, and VRUS, who have early-stage HCV nukes and non-nukes in their pipelines.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today